In an oral presentation entitled “A Phase II trial of KRX-0401 (perifosine) in patients with chemo-insensitive sarcomas: preliminary results,” Dr Joseph Ludwig assistant professor, dept of sarcoma, MD Anderson Cancer Center reported on preliminary Phase II data in which single agent perifosine demonstrated a 40% overall clinical benefit (Stable Disease > 3 months) in these subsets of patients. Perifosine was also well tolerated with the most common grade 1 and 2 adverse events reported as nausea, vomiting, diarrhea and fatigue.
Dr Craig Henderson, president of Keryx, said: “We continue to remain encouraged by the demonstrated clinical activity of perifosine in these rare but unresponsive sarcomas. We are excited to be working with the team of SARC investigators on this important clinical study and look forward to completing accrual to all study arms in 2008.”